

**Accuracy of the new Barrett TAL formula with the Argos  
measurements: A multicenter prospective study**  
*An investigator-initiated clinical trial*

**1. TITLE PAGE**

Protocol Number: HJS-23-01

Amendment Number Version 1.0

IRB / ERC Salus IRB  
2111 West Braker Lane, Suite 400  
Austin, Texas 78758

Sponsor Name & Address: H. John Shammas, MD  
Shammas Eye Medical Center  
3510 Martin Luther King Jr. Blvd  
Lynwood, CA 90262

***(funding only, this is an investigator-initiated study  
IIT # 89167025)***

Alcon  
6201 South Freeway,  
Fort Worth, TX 76134-2099, USA

Test Articles: Argos Biometer

## 2 . INVESTIGATOR AGREEMENT

**I confirm that I have read and that I understand this protocol entitled “Accuracy of the new Barrett TAL formula with the Argos measurements: A multicenter prospective study”, and understand the use of the study products. I agree to conduct this study in accordance with the requirements of this protocol and also protect the rights, safety, privacy, and well-being of study subjects in accordance with the following:**

- The ethical principles that have their origin in the Declaration of Helsinki.
- All applicable laws and regulations, including, without limitation, data privacy laws and regulations.
- Regulatory requirements for reporting serious adverse events defined in Section 13 of this protocol.

---

Signature of Investigator (Date)

---

Investigator Name (print or type)

---

Investigator’s Title

---

Name of Facility

---

Location of Facility (City)

### 3. GENERAL INFORMATION

Objective	<p>To evaluate the clinical outcomes from cataract surgery in eyes measured with the Argos biometer using the new Barrett True Axial Length (BTAL) formula, and compare to potential results with the Barrett Universal II (BUII) formula.</p> <p>The hypothesis is that there will be a better refractive predictability of Argos measurements with the BTAL formula compared to the Barrett Universal II formula in the entire series.</p>
Test Article(s)	Argos Biometer
Control Article(s)	None.
Sample size	590 eyes of 590 subjects
Study Population	Subjects of who are appropriate candidates for cataract surgery.
Study Design	Prospective, multi-site, multi-surgeon, observational study
Masking	None
Variables	<p>Primary: The percentage of eyes that achieve a postoperative manifest spherical equivalent refraction <math>\leq \pm 0.50</math> D.</p> <p>Secondary:</p> <ul style="list-style-type: none"><li>• The percentage of eyes that achieve a postoperative manifest spherical equivalent refraction <math>\leq \pm 0.250</math> D, <math>\leq \pm 0.75</math> D and <math>\leq \pm 1.00</math> D.</li><li>• The Mean Predictive Error and its standard deviation after constant personalization for the entire series.</li><li>• The Mean Predictive Errors in the short eyes and in the long eyes (Short AL &lt; 22.5mm, Long AL &gt; 24.5mm and Medium AL 22.6mm to 24.4mm), and the percentage of eyes that achieve a postoperative manifest spherical equivalent refraction <math>\leq \pm 0.25</math> D, <math>\leq \pm 0.50</math> D, <math>\leq \pm 0.75</math> D and <math>\leq \pm 1.00</math> D in each of these categories.</li></ul>
Duration / Follow-up	Preoperative to 2 months postoperative

***The study will be registered with [clinicaltrials.gov](https://clinicaltrials.gov). The study will be conducted in compliance with the protocol, GCP and applicable regulatory requirements.***

#### 4. TABLE OF CONTENTS

1. TITLE PAGE.....	1
2 . INVESTIGATOR AGREEMENT .....	2
3. GENERAL INFORMATION.....	3
4. TABLE OF CONTENTS .....	4
5. INTRODUCTION .....	6
6. OBJECTIVE(S) .....	6
7. SUBJECTS .....	6
7.1. Subject Population .....	6
7.2. Inclusion Criteria .....	6
7.3. Exclusion Criteria.....	7
8. STUDY DESIGN .....	7
8.1. Study Design.....	7
8.2. Methods Used to Minimize Bias.....	8
9. STUDY PROCEDURE .....	8
9.1. Informed Consent / Subject enrollment .....	8
9.2. Visits and Examinations.....	8
9.3. Study Methods and Measurements.....	10
9.4. Unscheduled Visits .....	10
9.5. Discontinued Subjects .....	10
10. ANALYSIS PLAN .....	11
10.1. Analysis Data Sets.....	11
10.2. Statistical Methodology .....	11
10.3. General Statistical Considerations .....	11
11. SAMPLE SIZE JUSTIFICATION .....	11
12. CONFIDENTIALITY/PUBLICATION OF THE STUDY .....	12
13. QUALITY COMPLAINTS AND ADVERSE EVENTS .....	12
13.1. General Information.....	12
13.2. Monitoring for Adverse Events .....	13
13.3. Procedures for Recording and Reporting AEs and SAEs.....	13
13.4. Follow-Up of Adverse Events and Quality Complaints .....	16

13.5. Safety Analyses.....	16
14. GCP, ICH and ETHICAL CONSIDERATIONS .....	16
14.1 Confidentiality .....	16
15. STANDARD EVALUATION PROCEDURES .....	17
Table 15.1. Proposed Visits and Study Assessments .....	17
16. CONFIDENTIALITY.....	17
17. FINANCIAL AND INSURANCE INFORMATION/STUDY RELATED INJURIES.....	17
18. STUDY ENDPOINT CRITERIA .....	18
18.1. Patient Completion of Study .....	18
18.2. Patient Discontinuation.....	18
18.3. Patient Termination .....	18
18.4. Study Termination .....	18
18.5. Study Completion.....	18
19. SUMMARY OF RISKS AND BENEFITS.....	18
19.1. Summary of risks .....	18
19.2. Summary of benefits .....	18
REFERENCES .....	19

## 5. INTRODUCTION

Cataract surgery is a refractive procedure, and patients and surgeons are hopeful to achieve both clearer vision and a reduction in spectacle dependence with each outcome. Refractive accuracy depends on multiple factors, especially precise measurements of pre-operative keratometry and axial length.

The Argos swept-source optical coherence biometer measures the optical path length of the eye using a sum-of-segments method by using a specific refractive index for each of the eye segments (cornea, anterior chamber, lens and vitreous),<sup>1</sup> contrary to other optical biometers that use a single variable refractive equation to convert the optical path length into a geometric value. As such, when there are variations in the relative length of different eye components, the axial length calculation is appropriately adjusted with the Argos. This approach is intended to provide more accurate IOL power calculations in long and short eyes.<sup>2</sup> In a recent retrospective study,<sup>1</sup> Argos using the Barrett TAL (True Axial Length) performed well.

The purpose of this study is to evaluate the clinical outcomes from cataract surgery in eyes measured with the Argos biometer using the new Barrett TAL formula, and compare to potential results with the Barrett Universal II formula.

## 6. OBJECTIVE(S)

To compare the clinical outcomes from cataract surgery in eyes measured with the Argos biometer using the new Barrett TAL formula, and compare to potential results with the Barrett Universal II formula.

## 7. SUBJECTS

### *7.1. Subject Population*

Eligible test subjects will be adults who are interested in and appropriate candidates for cataract surgery.

A total of 590 eyes of 590 subjects will be enrolled. One eye of each subject will be enrolled. Subjects must meet the inclusion criteria. Prior to enrollment, subjects will be provided information on the study and asked to sign a patient information and consent form to participate. The patient information and consent form will be approved by an appropriate ethics committee.

### *7.2. Inclusion Criteria*

Subjects are eligible for the study if they meet the following criteria:

**Note:** Ocular criteria must be met in both eyes.

- Cataract surgery that was completed without complications with biometry measured using the Argos biometer.

- Subjects that elect Clareon SY60WF aspheric lens (Alcon, Fort Worth, TX).
- Potential post-operative visual acuity of better than logMAR 0.30 (20/40).
- BTAL was used to determine the IOL power implanted.

### **7.3. Exclusion Criteria**

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

- Patients with pre-existing ocular pathology that in the opinion of the principal investigator would influence the postoperative refraction.
- Any disease or pathology, including but not limited to irregular corneal astigmatism and keratoconus, that is expected to reduce the potential postoperative BCDVA to a level worse than 20/40.
- Patients with history of previous ocular surgery.
- Patients with signs of inability to understand consent for study and procedure planned.
- Eyes with intraoperative or postoperative complications.
- Suboptimal surgical outcomes that are not related to the treatment plan, e.g. capsular tear, cystoid macular edema.
- Astigmatism  $>\pm 0.75\text{D}$ .

Each investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

## **8. STUDY DESIGN**

### **8.1. Study Design**

This study is a Prospective, multi-site, multi-surgeon, observational study of refractive accuracy with the Argos using BTAL after successful cataract surgery. Subjects will be assessed pre-operatively, operatively and at 5-8 weeks postoperatively. Clinical evaluations will include measurement of visual acuity, manifest refraction, and preoperative biometry.

The primary outcome measure will be the percentage of eyes that achieve a postoperative manifest spherical equivalent refraction  $\leq \pm 0.50\text{ D}$ .

Secondary outcome measures are as follows:

- The percentage of eyes that achieve a postoperative manifest spherical equivalent refraction  $\leq \pm 0.250\text{D}$ ,  $\leq \pm 0.75\text{D}$  and  $\leq \pm 1.00\text{D}$ .
- The Mean Predictive Error and its standard deviation after constant personalization for the entire series.
- The Mean Predictive Errors in the short eyes and in the long eyes (Short AL < 22.5mm, Long AL > 24.5mm and Medium AL 22.6mm to 24.4mm), and the percentage of eyes that achieve a postoperative manifest spherical equivalent refraction  $\leq \pm 0.25\text{ D}$ ,  $\leq \pm 0.50\text{ D}$ ,  $\leq \pm 0.75\text{ D}$  and  $\leq \pm 1.00\text{ D}$  in each of these categories.

## 8.2. Methods Used to Minimize Bias

As an observational study there is no expected bias. Patient selection will be based on the patient's interest and the surgeon's opinion as to whether they are a suitable candidate for cataract surgery.

The measurement of visual acuity will be conducted in a systematic fashion to minimize bias. Individuals conducting visual acuity measures will be instructed to perform the same testing in the same fashion for all subjects, with the same level of encouragement to subjects.

All data collection will be completed through provided Case Report Forms (CRFs) or computer files generated by automated test equipment. All site personnel involved in the study will be trained in regard to conducting study-specific procedures.

## 9. STUDY PROCEDURE

### 9.1. Informed Consent / Subject enrollment

No subject will be enrolled into the study who does not meet the inclusion/exclusion criteria and does not sign the current approved informed consent document. Informed consent will be obtained prior to collecting any data for the study. The original signed documents will be maintained by the investigator as a permanent part of the subject's medical records. A signed copy will be provided to the subject.

### 9.2. Visits and Examinations

Subjects will participate in 3 study visits, including one visit for surgery. Visits will include an uptake visit, one operative visit, and 1 postoperative visit (Visit numbers 1-3 below). The visit schedule, complete with window, are displayed in Table 9.2-1. Details of each study visit, including testing to be conducted, are provided below.

**Table 9.2-1. Visit Schedule**

Visit Number	Visit Name	Visit Window
1	Preoperative	-90 to 0 days from surgery
2	Operative	0 from surgery

3                      2 Months Postoperative                      5 to 8 weeks postoperative

### 9.2.1. Preoperative

At the preoperative exam, subjects will be consented, qualified for the study (compared with inclusion/exclusion criteria), and assigned a study ID/subject number. Subject numbers will be assigned sequentially at each site in the order of enrollment. Pre-operative qualification should take place no more than 90 days prior to surgery.

A medical history will be taken and exams will include the tests described below:

- manifest refraction,
- visual acuity,
- topography,
- biometry,
- dilated fundus exam,
- slit-lamp exam

In addition, all site-specific, routine, usual standard of care preoperative measures should be undertaken. Measurements should be made as described in section 9.3 below.

### 9.2.2. Operative (Surgery)

All subjects will undergo cataract surgery and lens implantation. The surgeon's usual standard of care with regard to treatment and medication will be used for all study subjects. Preoperative planning will be performed using BTAL formula.

Any adverse events/serious adverse events (AEs/ SAEs) occurring during surgery will be noted at this visit. Any other problems during surgery and comments regarding surgery will be documented.

Any subject whose surgery is not completed successfully will be documented in the appropriate case report form. These subjects will be monitored for safety but clinical performance data may be excluded from the analysis.

### 9.2.3. Postoperative Visit

All routine, usual standard of care postoperative measures should be undertaken. In addition, the subject will undergo a manifest refraction and VA testing. (Section 9.3). Any device deficiencies or adverse events will be monitored.

### 9.2.4. Exit Procedures

In the event of premature exit from the study, all study related examinations should be completed where possible. The Exit CRF should be completed, noting that the subject did not complete the study and the reason for premature study exit. If no premature exit from the study occurs, the Exit CRF should be completed at the end of Visit 3.

### ***9.3. Study Methods and Measurements***

All routine testing and basic eye examinations should be carried out at each study visit. Abnormalities should be recorded in the CRF “Comment” section. Specific study examination procedures are outlined below.

#### ***9.3.1. Manifest Refraction***

Perform a manifest refraction with a high contrast Snellen chart under photopic lighting conditions. Document refraction results with sphere, cylinder and axis readings. If uncorrected visual acuity is not improved by manifest refraction, use zero for sphere and cylinder and draw a line through the blank for the axis.

**Note:** Each subject should be manually refracted to his/her best correction by an ophthalmologist, optometrist, or a skilled technician using a phoropter or trial lenses.

#### ***9.3.2. Visual Acuity (VA)***

##### ***Distance VA***

Measure distance visual acuity using a high contrast ETDRS chart under photopic lighting at a distance of 20 ft or equivalent. Please record visual acuity in logMAR.

### ***9.4. Unscheduled Visits***

Unscheduled exams may be conducted at the discretion of the Investigator with all relevant information from the exam recorded in the source documents and on the Unscheduled Visit pages within the CRF booklet.

### ***9.5. Discontinued Subjects***

Discontinued subjects are those who do not have an exit visit or who come into the office to be exited prior to the scheduled final study visit. Subjects may be discontinued from the study at any time if, in the opinion of the investigator, their continued participation in the study poses a risk to their health. The reasons for discontinuation include:

- a. Adverse event;
- b. Lost to follow-up;
- c. Subject decision unrelated to an adverse event;
- d. Protocol violation;
- e. Treatment failure;
- f. Other.

To ensure the safety of all subjects who discontinue prior to Visit 3, investigators should assess each subject and, if necessary, advise them of any therapies and/or medical procedures that might be needed to maintain their health. Any changes in medical health and/or use of concomitant medications should also be captured.

## **10. ANALYSIS PLAN**

### ***10.1. Analysis Data Sets***

All subjects who are enrolled in the study will be evaluated for safety. Efficacy analyses will be performed based on data from those eyes with uncomplicated cataract surgery.

### ***10.2. Statistical Methodology***

A summary of the data will be prepared for all measurement time points.

A summary of the data will be prepared for all measurements. For variables measured on a continuous scale, these summaries will include the sample size, as well as the mean, standard deviation, median, minimum, and maximum. For variables measured on a categorical scale, summaries will provide the number and percentage of eyes in each category. These summaries will be provided for all eyes completing the study.

#### **10.2.1. Within-treatment Changes**

The percentage of eyes within  $\pm 0.50D$  of predicted post-op spherical equivalent using ARGOS with both Barrett True Axial Length and Barrett Universal II formulas will be compared using the McNemar test.

Comparison of formula performance (mean absolute prediction error) will be done by the heteroscedastic (HC) method.<sup>3</sup> For variables measured on a continuous scale, the statistical significance of each parameter will be investigated using a paired t-test (for parametric data) or a Wilcoxon signed-rank test (for non-parametric data).

### ***10.3. General Statistical Considerations***

The statistical analysis will be performed using R, version 4.2.2 or higher. Any statistical tests of hypotheses will employ a level of significance of  $\alpha=0.05$ .

## **11. SAMPLE SIZE JUSTIFICATION**

We estimate the sample size required for detecting a difference of 0.08 between the percentage of long eyes with absolute prediction error 0.5 D or better (90% compared to 82%), power of 97%, correlation between paired observations 0.85, and a two sided significance of 5% is 116.

We also estimate the sample size required for detecting a difference of 0.10 between the percentage of short eyes with absolute prediction error 0.5 D or better (BTAL compared

to 76%), power of 97%, correlation between paired observations 0.85, and a two sided significance of 5% is 93.

We also estimate the sample size required for detecting a difference of 0.05 between the percentage of medium eyes with absolute prediction error 0.5 D or better (85% compared to 80%), power of 97%, correlation between paired observations 0.85, and a two sided significance of 5% is 292.

for a total sample size of 501. Accounting for attrition of 15%, 590.

## **12. CONFIDENTIALITY/PUBLICATION OF THE STUDY**

The existence of this Study is confidential and should not be discussed with persons outside of the Study. Results will be submitted for publication and presentation at national and/or international meetings. A manuscript will be submitted to peer-review journals for publication but there is no guarantee of acceptance.

All study data will be collected on appropriate Case Report Forms (CRFs) or computer files generated by automated test equipment. No protected health information will be included on the forms. CRFs will be retained in the patient's file for a minimum period of 3 years. Collected information will only be used for purposes of this study and no information will be sold to third parties. The following people will have access to your study records:

- Study Doctor and staff involved with the study
- Study Monitor or Auditor
- Sponsor Company or Research Institution
- Review boards or accrediting agencies
- Other State or Federal Regulatory Agencies

The de-identified data may be shared with other researchers for future analysis.

## **13. QUALITY COMPLAINTS AND ADVERSE EVENTS**

All subjects will be monitored for adverse events over the course of the study. A place to record any adverse event is included on each case report form.

### ***13.1. General Information***

An Adverse Event (AE) is any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, can be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment. In clinical

studies, an AE can include an untoward medical occurrence occurring at any time, including run-in or washout periods, even if no study treatment has been administered.

### ***13.2. Monitoring for Adverse Events***

At each visit, after the subject has had the opportunity to spontaneously mention any problems, the Investigator should inquire about AEs by asking if the patient has any problems.

### ***13.3. Procedures for Recording and Reporting AEs and SAEs***

Subsequent to signing an informed consent form, all untoward medical occurrences that occur during the course of the study must be documented on an Adverse Event Form (AEF). A separate AEF must be filled out for each event. When possible, signs and symptoms indicating a common underlying pathology should be documented as one comprehensive event. For each recorded event, the AE documentation must include the onset date, outcome, resolution date (if event is resolved), intensity (i.e., severity), any action with study treatment taken as a result of the event, and an assessment of the adverse event's relationship to the study treatment.

#### **Nonserious Adverse Events**

A nonserious AE is defined as any untoward change in a subject's medical health that does not meet serious criteria noted below (e.g., is not life-threatening, does not require hospitalization, does not prolong a current hospitalization, is not disabling, etc.). All adverse events must be reported regardless of whether or not they are related to the study treatment.

For nonserious adverse events, an AEF containing all available information will be collected on a routine basis and submitted to the Medical Monitor at the close of the study.

#### **Serious Adverse Events**

A serious adverse event (SAE) is defined as any adverse experience that meets any of the following criteria:

- Results in death.
- Is life-threatening.

NOTE: Life-threatening means that the subject was at immediate risk of death from the reaction as it occurred; i.e., it does not include a reaction which hypothetically might have caused death had it occurred in a more severe form.

- Requires inpatient hospitalization or prolongation of existing hospitalization.

NOTE: In general, hospitalization signifies that the individual remained at the hospital or emergency ward for observation and/or treatment (usually involving an overnight stay) that would not have been appropriate in the physician's office or an out-patient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether "hospitalization" occurred, the event should be considered serious.

- Results in persistent or significant disability/incapacity. Disability is defined as a substantial disruption of a person's ability to conduct normal life functions.  
NOTE: The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, or accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.
- Is an important medical event. An important medical event is an event that may not result in death, be life-threatening, or require hospitalization but may be considered an SAE when, based upon appropriate medical judgment, it may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions for SAEs. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in subject hospitalization, or the development of drug dependency or drug abuse.  
All available information on a serious adverse event(s) and any other associated AE, if applicable, must be forwarded to the study coordinator for forwarding to the Medical Monitor immediately (i.e., within one working day of the Investigator's or site's knowledge of the event) as follows:
  - In studies utilizing EDC (electronic data capture), all available information for the SAE and any associated AE(s) must be entered immediately into the EDC system.
  - Additional information for any applicable event is to be reported as soon as it becomes available.

In addition to the reporting of serious adverse events to the study Medical Monitor, the SAE must be reported to the IRB / IEC according to their requirements.

The investigator must document all adverse device events (serious and nonserious but related) and all serious adverse events (related and unrelated) on the Adverse Device Effect and Serious Adverse Event Form. Any device quality complaints will also be documented.

- **Both the Quality Complaint Form and the Adverse Device Effect and Serious Adverse Event Form must be e-mailed immediately to the Sponsor.**
- **Additional relevant information is to be reported as soon as it becomes available.**

**Table 13.3.-1:  
Contact Information for Study**

<b>Study Sponsor</b>	<b>e-mail</b>
<b>H. John Shammass, MD</b>	<b>hshammass@aol.com</b>

Further, depending upon the nature of the adverse event (serious or nonserious) or quality complaint being reported, the study sponsor may request copies of applicable portions of the subject's medical records. The investigator must also report all adverse events and quality complaints according to the relevant IRB requirements.

#### 12.3.1 Intensity and Causality Assessments

For every adverse event and quality complaint, the investigator must assess the causality as Related or Not Related to the medical device under investigation. An assessment of causality will also be performed by the Medical Monitor utilizing the same definitions, as shown below:

##### ***Causality***

- |             |  |
|-------------|--|
| Related     | An adverse event or quality complaint classified as related may be either definitely related or possibly related where a direct cause and effect relationship with the medical device has not been demonstrated, but there is a reasonable possibility that the adverse event or quality complaint was caused by the medical device. |
| Not Related | An adverse event or quality complaint classified as not related may either be definitely unrelated or simply unlikely to be related (i.e., there are other more likely causes for the adverse event or quality complaint).   |

Where appropriate, the investigator must assess the intensity (severity) of the adverse event as mild, moderate, or severe based on medical judgment with consideration of any subjective symptom(s), as defined below:

##### ***Intensity (Severity)***

- |          |   |
|----------|---|
| Mild     | An adverse event is mild if the subject is aware of but can easily tolerate the sign or symptom.  |
| Moderate | An adverse event is moderate if the sign or symptom results in discomfort significant enough to cause interference with the subject's usual activities. |
| Severe   | An adverse event is severe if the sign or symptom is incapacitating and results in the subject's inability to work or engage in their usual activities. |

The investigator must document any action taken (i.e., medication, intervention, or treatment plan) and outcome of the adverse event or quality complaint when applicable.

#### ***13.4. Follow-Up of Adverse Events and Quality Complaints***

The investigator is responsible for adequate and safe medical care of subjects during the study and for ensuring that appropriate medical care and relevant follow-up procedures are maintained after the study. Any additional data from these follow-up procedures must be documented and available to the study coordinator who, with the Medical Monitor, will determine when the data need to be documented on the CRFs.

#### ***13.5. Safety Analyses***

The type, severity, duration and frequency of reported ocular adverse events will be tabulated. Adverse events will also be summarized for events that were considered treatment-related.

### **14. GCP, ICH and ETHICAL CONSIDERATIONS**

This study will be conducted in compliance with Good Clinical Practices (GCPs), including International Harmonization (ICH) Guidelines, and in general, consistent with the 1996 version of the Declaration of Helsinki. In addition, all applicable local, state and federal requirements will be adhered to.

This study is to be conducted in accordance with Institutional Review Board regulations. The investigator will obtain appropriate IRB/ethics committee approval prior to initiating the study.

The study will be registered with [clinicaltrials.gov](https://clinicaltrials.gov).

#### ***14.1 Confidentiality***

The data collected will be data typical for the procedure(s) when performed on eyes outside the study. Any data collected will become part of the patient's clinical record. The data will be subject to the same privacy and confidentiality as other data in the clinical record.

Only the principal investigator, research consultant and clinic staff will have access to the data collected. All data shared outside the practice will be de-identified; patients' protected health information will not be available and will not be reported in any analyses or publications. No data will be sold to third parties. De-identified data may be used for future research.

## 15. STANDARD EVALUATION PROCEDURES

**Table 15.1. Proposed Visits and Study Assessments**  
(visits are by patient, with both eyes tested)

Activity	Pre-operative	Operative	Post-Operative
	Visit 1	Visit 2	Visit 3
Informed Consent	X		
Demographics	X		
General Information: Medical History	X		
Surgery		X	
Manifest refraction	X		X
Monocular uncorrected distance VA	X		X
Monocular corrected distance VA	X		X
Biometry	X		
Topography	X		
Slit Lamp Exam	X		
Dilated Fundus Exam	X		
Monitor for Adverse Events and Device Deficiencies		X	X
Complete Exit Form <sup>1</sup>			X

<sup>1</sup> Complete Exit Form upon termination of subject participation, or at Visit 3, whichever occurs first.

## 16. CONFIDENTIALITY

No protected health information (PHI), including the patient's name and date of birth, will be collected; to ensure this, no PHI information is permitted to be entered on any of the Case Report Forms (CRFs). Subjects will only be identified by subject IDs and identities will be removed at the initial visit so that there is no further need to protect or destroy the information. Collected information will only be used for purposes of this study and no information will be sold to third parties. The non-PHI information collected may be used for future research, though there is currently no plan to do so.

## 17. FINANCIAL AND INSURANCE INFORMATION/STUDY RELATED INJURIES

Every effort to prevent study-related injury will be taken by the Study Doctor and staff. In the event a patient is injured as a direct result of the study while following the Study Doctor's instructions and the study requirements, the patient will be instructed to contact his or her doctor immediately. The Study Doctor is to treat the injured subject as needed for those injuries caused directly by this research study. In the event of injury or illness caused by or occurring during a subject's participation in this research study, all charges for medical care provided to the subject will be billed to his or her insurance company.

The Study Doctor or Sponsor does not offer to cover the medical care costs for injuries or illnesses that are not caused directly by the research study. The Sponsor does not offer to provide any other compensation, unless specifically agreed to elsewhere in this document. This information will be provided to each study subject before the start of the study in the consent form.

## **18. STUDY ENDPOINT CRITERIA**

### ***18.1. Patient Completion of Study***

If a study patient has completed the final visit (Visit 3) of the study, he/she is considered to have completed the study.

### ***18.2. Patient Discontinuation***

Each study patient may voluntarily discontinue the study at any time they choose. Study patients who cannot complete the study for administrative reasons (e.g., non-compliance, failure to meet visit schedule, etc.) will be discontinued from the study. Study patients discontinued during the enrollment phase (prior to surgery) of the study will be replaced.

### ***18.3. Patient Termination***

A study patient will be terminated if the study patient develops any severe adverse event that may be related to the study. A study patient will receive appropriate treatment at the discretion of the investigator. Notification of termination will be clearly documented. These study patients are considered to have completed the study and will not be replaced.

### ***18.4. Study Termination***

The investigator with appropriate notification may terminate the study. If, after clinical observations, the investigator feels that it may be unwise to continue the study, he may stop the study.

### ***18.5. Study Completion***

The study will be complete when all enrolled patients have completed Visit 3 or have been terminated from the study.

## **19. SUMMARY OF RISKS AND BENEFITS**

### ***19.1. Summary of risks***

The risks with this study are similar to those for any patient receiving bilateral cataract surgery.<sup>1</sup> There is no increased risk associated with the proposed study.

### ***19.2. Summary of benefits***

Previous studies have shown that the Argos (Alcon, Fort Worth, Texas, USA) with BTAL provides good visual outcomes for patients.<sup>1</sup>

**REFERENCES**

1. Shammas HJ, Taroni L, Pellegrini M, Shammas MC, Jivrajka RV. Accuracy of newer intraocular lens power formulas in short and long eyes using sum-of-segments biometry. *J Cataract Refract Surg*. 2022;48(10):1113-1120.
2. Shammas HJ, Shammas MC, Jivrajka RV, Cooke DL, Potvin R. Effects on IOL power calculation and expected clinical outcomes of axial length measurements based on multiple vs single refractive indices. *Clin Ophthalmol*. 2020;14:1511-1519.
3. Holladay JT, Wilcox RR, Koch DD, Wang L. Review and recommendations for univariate statistical analysis of spherical equivalent prediction error for IOL power calculations. *J Cataract Refract Surg*. 2021;47(1):65-77.